Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial

Arman Faravardeh; Sanjeev Akkina; Rafael Villicana; Giselle Guerra; Misbah A. Moten; Ulf Meier-Kriesche; Daniel R. Stevens; Samir J. Patel; Suphamai Bunnapradist

doi:10.12659/AOT.929535

16 April 2021 : Original article

Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial

Arman Faravardeh^1DE*, Sanjeev Akkina^2DE, Rafael Villicana^3DE, Giselle Guerra^4DE, Misbah A. Moten^5ADE, Ulf Meier-Kriesche^5ADE, Daniel R. Stevens^5ACDE, Samir J. Patel^5DE, Suphamai Bunnapradist^6DE

DOI: 10.12659/AOT.929535

Ann Transplant 2021; 26:e929535

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 TDD (A), tacrolimus trough concentration (B), and the ratio of tacrolimus trough concentration to TDD (C) in Hispanic/Latino stable kidney transplant recipients. P values were calculated by general linear model for fixed effect of treatment×time. CI – confidence interval; IR-Tac – immediate-release tacrolimus; LCPT – LCP-tacrolimus; TDD – total daily dose.

Back to the Article

Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial

Your Privacy